NEWAMSTERDAM PHARMA CO NV

Newamsterdam Pharma’s shares slump 7.9% after breaching a 200‑day SMA, revealing a mismatch between lofty drug‑pipeline claims and weak trading volume. Investors should weigh the gap between hype and tangible regulatory milestones before buying.

Newamsterdam Pharma (NAMS) shares dip 0.05% to $21.58 as a $2.6B biopharma company focuses on oral cardiovascular therapies.

Newamsterdam Pharma shares rise 5% to $21.50, with a $2.5 B market cap. Discover the latest market metrics, 52‑week range, and analyst insights for this biotech leader.